6 days Ago By Defense World Staff
Renaissance Technologies LLC increased its position in Adaptimmune Therapeutics plc ( NASDAQ:ADAP – Free Report ) by 52.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,526,524 shares of the biotechnology company’s stock after buying an additional 869,949 shares during the quarter.
Renaissance Technologies LLC owned about 0.99% of Adaptimmune Therapeutics worth $1,361,000 at the end of the most recent reporting period. Several other large investors have also bought and sold shares of the company.
Jane Street Group LLC lifted its holdings in Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares during the last quarter.
Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 21,769 shares during the last quarter.
Invesco Ltd. boosted its stake in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter.
Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Adaptimmune Therapeutics by 106.
5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. Institutional investors own 31.
37% of the company’s stock. Analysts Set New Price Targets A number of equities analysts recently weighed in on the company. StockNews.
com initiated coverage on Adaptimmune Therapeutics in a research report on Tuesday, April 22nd. They issued a “buy” rating for the company. HC Wainwright decreased their target price on shares of Adaptimmune Therapeutics from $3.
50 to $3.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Jones Trading lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th.
Guggenheim decreased their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th.
Finally, Wells Fargo & Company lowered their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday, March 21st.
Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Adaptimmune Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $1.83.
Adaptimmune Therapeutics Stock Performance Shares of ADAP opened at $0.28 on Tuesday. The company has a market capitalization of $71.
28 million, a PE ratio of -1.26 and a beta of 2.84.
The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.
85. The company’s 50 day moving average price is $0.35 and its 200 day moving average price is $0.
55. Adaptimmune Therapeutics plc has a 52 week low of $0.20 and a 52 week high of $1.
48. Adaptimmune Therapeutics ( NASDAQ:ADAP – Get Free Report ) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.
26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).
Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.
The firm had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $16.56 million.
Research analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year. About Adaptimmune Therapeutics ( Free Report ) Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. Recommended Stories Five stocks we like better than Adaptimmune Therapeutics Retail Stocks Investing, Explained Best Defense Stocks in 2025..
. So Far Options Trading – Understanding Strike Price Alphabet Rebounds After Strong Earnings and Buyback Announcement What is the Nikkei 225 index? Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
